低剂量放射治疗新型冠状病毒肺炎患者：一项单机构前瞻性研究
Low-Dose Radiotherapy for Patients with Pneumonia Due to COVID-19: A Single-Institution Prospective Study.
作者信息
Rutkowski Tomasz Wojciech, Jaroszewicz Jerzy, Piotrowski Damian, Ślosarek Krzysztof, Sobala-Szczygieł Barbara, Słonina Dorota, Włostowska Bożena, Bodusz Dawid, Piasecki Maciej, Nachlik Michał, Oczko-Grzesik Barbara, Gądek Adam, Kowal Dorota, Rutkowski Roman, Wojarska-Tręda Elżbieta, Składowski Krzysztof
机构信息
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, ul. Wybrzeże Armii Krajowej 15, 44-100 Gliwice, Poland.
Department of Infectious Diseases and Hepatology, Medical University of Silesia, 41-902 Bytom, Poland.
出版信息
Biomedicines. 2023 Mar 11;11(3):858. doi: 10.3390/biomedicines11030858.
PURPOSE
Results of the low-dose radiation therapy (LDRT) in patients with pneumonia due to COVID-19 has been presented.
METHODS
Fifteen patients received a single-fraction radiation dose of 1 Gy to the bilateral lungs due to pre-ARDS pneumonia in the course of COVID-19. Follow-up was performed on days 1, 3, 5, 7, 14 after LDRT.
RESULTS
Eleven patients (73%) were released up until day 28. Median hospitalization was 20 days; 28-day mortality was 13%. Median O saturation improved within 24 h after LDRT in 14/15, with median SpO values of 84.5% vs. 87.5% = 0.016, respectively. At day 14 of hospitalization, 46% did not require oxygen supplementation. Significant decline in CRP and IL-6 was observed within 24 h post LDRT. No organ toxicities were noted.
CONCLUSION
LDRT is feasible, well tolerated and may translate to early clinical recovery in patients with severe pneumonia. Further studies are needed to determine optimal candidate, time and dose of LDRT for COVID-19 patients with pneumonia.
目的
已公布低剂量放射治疗（LDRT）对新型冠状病毒肺炎（COVID-19）所致肺炎患者的治疗结果。
方法
15例因COVID-19病程中出现急性呼吸窘迫综合征（ARDS）前期肺炎而接受双侧肺单次1 Gy放射剂量治疗的患者。在LDRT后第1、3、5、7、14天进行随访。
结果
截至第28天，11例患者（73%）出院。中位住院时间为20天；28天死亡率为13%。14/15例患者在LDRT后24小时内中位血氧饱和度有所改善，中位SpO值分别为84.5%和87.5%，P = 0.016。住院第14天时，46%的患者无需吸氧。LDRT后24小时内观察到CRP和IL-6显著下降。未发现器官毒性。
结论
LDRT是可行的，耐受性良好，可能有助于重症肺炎患者的早期临床康复。需要进一步研究以确定COVID-19肺炎患者LDRT的最佳候选者、时间和剂量。
Zotero 插件